126 related articles for article (PubMed ID: 18042071)
1. The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast.
Lee AH; Paish EC; Marchio C; Sapino A; Schmitt FC; Ellis IO; Reis-Filho JS
Histopathology; 2007 Dec; 51(6):824-8. PubMed ID: 18042071
[TBL] [Abstract][Full Text] [Related]
2. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?
Moritani S; Ichihara S; Hasegawa M; Endo T; Oiwa M; Yoshikawa K; Sato Y; Aoyama H; Hayashi T; Kushima R
Hum Pathol; 2008 May; 39(5):666-71. PubMed ID: 18339419
[TBL] [Abstract][Full Text] [Related]
3. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
Tornos C; Soslow R; Chen S; Akram M; Hummer AJ; Abu-Rustum N; Norton L; Tan LK
Am J Surg Pathol; 2005 Nov; 29(11):1482-9. PubMed ID: 16224215
[TBL] [Abstract][Full Text] [Related]
4. WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes.
Domfeh AB; Carley AL; Striebel JM; Karabakhtsian RG; Florea AV; McManus K; Beriwal S; Bhargava R
Mod Pathol; 2008 Oct; 21(10):1217-23. PubMed ID: 18469795
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
Sangoi AR; Higgins JP; Rouse RV; Schneider AG; McKenney JK
Mod Pathol; 2009 May; 22(5):660-7. PubMed ID: 19270645
[TBL] [Abstract][Full Text] [Related]
6. Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report.
Maeshima Y; Osako T; Morizono H; Yunokawa M; Miyagi Y; Kikuchi M; Ueno T; Ohno S; Akiyama F
J Med Case Rep; 2021 Feb; 15(1):78. PubMed ID: 33593410
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
8. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
[TBL] [Abstract][Full Text] [Related]
9. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
10. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
11. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.
Acs G; Pasha T; Zhang PJ
Int J Gynecol Pathol; 2004 Apr; 23(2):110-8. PubMed ID: 15084838
[TBL] [Abstract][Full Text] [Related]
12. Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
Ramalingam P; Middleton LP; Tamboli P; Troncoso P; Silva EG; Ayala AG
Ann Diagn Pathol; 2003 Apr; 7(2):112-9. PubMed ID: 12715337
[TBL] [Abstract][Full Text] [Related]
13. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion.
Prat J; De Nictolis M
Am J Surg Pathol; 2002 Sep; 26(9):1111-28. PubMed ID: 12218568
[TBL] [Abstract][Full Text] [Related]
14. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
15. CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin.
Keen CE; Szakacs S; Okon E; Rubin JS; Bryant BM
Histopathology; 1999 Feb; 34(2):113-7. PubMed ID: 10064389
[TBL] [Abstract][Full Text] [Related]
16. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
17. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
19. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
20. Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach.
Armes JE; Bowlay G; Lourie R; Venter DJ; Price G
Pathology; 2010; 42(6):534-9. PubMed ID: 20854071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
